Biotech
17 July 2026 Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture.
More News
2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.
2 July 2026 The firm has appointed two new partners in Basel and Bristol, adding decades of expertise from the pharmaceutical and biotech sectors to its growing life sciences practice.
29 June 2026 The newly combined transatlantic firm brings together more than 950 partners across 20 countries, uniting leading patent, trade secrets, life sciences, and tech practices.
26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.
25 June 2026 The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.
25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.
24 June 2026 Weight loss drugs promise a diabetes breakthrough in Africa, but patent barriers stall access. What does COVID-19 tell us about how to solve the continent’s silent crisis? Asks Sofia Araújo of Inventa.
Latest Features
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotech
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox